PTC Therapeutics, Inc. (PTCT) Insider Trading

Last 12 months

Insiders sold $57.9M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Dec 2023.

Net open-market

−$57.9M

0 buys · 70 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 13

executives and directors

Last open-market buy

Dec 2023

Dec 12, 2023

Get an email when PTCT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 14	Michael Schmertzler Director	Sold10b5-1 plan 2 parts	2,500	$59.61 average	$149k	0.2%	Form 4
Oct 9	Mark Elliott Boulding EXEC. VP AND CLO	Sold10b5-1 plan	192	$64.26	$12k	0.2%	Form 4
Oct 7	Michael Schmertzler Director	Sold10b5-1 plan 2 parts	2,500	$63.39 average	$158k	0.2%	Form 4
Oct 5 – 6	Mark Elliott Boulding EXEC. VP AND CLO	Sold10b5-1 plan 2 parts	2,073	$64.06 average	$133k	1.9%	Form 4
Sep 30	Glenn Jr Md Phd Steele Director	Sold10b5-1 plan	12,000	$65.16	$782k	35%	Form 4
Sep 16 – 17	Michael Schmertzler Director	Sold10b5-1 plan 4 parts	20,000	$67.49 average	$1.35M	1.4%	Form 4
Sep 9 – 10	Michael Schmertzler Director	Sold10b5-1 plan 3 parts	20,000	$67.59 average	$1.35M	1.5%	Form 4
Aug 26 – 27	Michael Schmertzler Director	Sold10b5-1 plan 4 parts	25,000	$72.26 average	$1.81M	1.6%	Form 4
Aug 19 – 20	Michael Schmertzler Director	Sold10b5-1 plan 5 parts	25,000	$72.22 average	$1.81M	1.6%	Form 4
Aug 17	Mark Elliott Boulding EXEC. VP AND CLO	Sold10b5-1 plan 2 parts	2,813	$72.57 average	$204k	2.6%	Form 4
Aug 4	Matthew B. Klein CHIEF EXECUTIVE OFFICER	Sold10b5-1 plan	10,292	$68.57	$706k	2.6%	Form 4
Jul 14	Pierre Gravier CHIEF FINANCIAL OFFICER	Sold10b5-1 plan	3,494	$80.35	$281k	4.0%	Form 4
Jul 9	Mary L. Smith Director	Sold10b5-1 plan 2 parts	15,834	$90.00 average	$1.43M	42%	Form 4
Jul 9	Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER	Sold10b5-1 plan	2,464	$90.25	$222k	3.8%	Form 4
Jul 6 – 7	Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER	Sold10b5-1 plan 8 parts	46,774	$87.52 average	$4.09M	43%	Form 4
Jul 6	Mark Elliott Boulding EXEC. VP AND CLO	Sold10b5-1 plan 8 parts	5,079	$85.08 average	$432k	4.6%	Form 4
Jun 26	Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER	Sold10b5-1 plan 2 parts	8,130	$85.26 average	$693k	11%	Form 4
Jun 24 – 25	Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER	Sold10b5-1 plan 7 parts	26,283	$85.78 average	$2.25M	30%	Form 4
Jun 22	Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER	Sold10b5-1 plan 2 parts	23,749	$80.90 average	$1.92M	27%	Form 4
Jun 17	Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER	Sold10b5-1 plan	19,686	$75.56	$1.49M	22%	Form 4
Jun 17	Mark Elliott Boulding EXEC. VP AND CLO	Sold10b5-1 plan 4 parts	10,462	$78.65 average	$823k	9.0%	Form 4
Jun 10	Eric Pauwels CHIEF BUSINESS OFFICER	Sold10b5-1 plan 2 parts	21,277	$75.00 average	$1.6M	22%	Form 4
May 15	Mark Elliott Boulding EXEC. VP AND CLO	Sold10b5-1 plan 2 parts	2,812	$72.18 average	$203k	2.6%	Form 4
May 14	Matthew B. Klein CHIEF EXECUTIVE OFFICER	Sold10b5-1 plan 4 parts	12,572	$72.95 average	$917k	3.1%	Form 4
May 8	Mark Elliott Boulding EXEC. VP AND CLO	Sold10b5-1 plan 4 parts	3,540	$78.97 average	$280k	3.3%	Form 4
Apr 21	Matthew B. Klein CHIEF EXECUTIVE OFFICER	Sold10b5-1 plan	2,850	$70.91	$202k	0.7%	Form 4
Apr 6	Mark Elliott Boulding EXEC. VP AND CLO	Sold10b5-1 plan 2 parts	2,265	$69.45 average	$157k	2.1%	Form 4
Apr 2	Lee Scott Golden EVP & CHIEF MEDICAL OFFICER	Sold10b5-1 plan	829	$67.99	$56k	1.0%	Form 4
Apr 1	Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER	Sold10b5-1 plan 3 parts	52,003	$69.04 average	$3.59M	45%	Form 4
Mar 12	Matthew B. Klein CHIEF EXECUTIVE OFFICER	Sold10b5-1 plan	2,662	$64.08	$171k	0.7%	Form 4
Mar 10	Stephanie Okey Director	Sold10b5-1 plan 2 parts	15,167	$70.00 average	$1.06M	65%	Form 4
Mar 5	Stephanie Okey Director	Sold10b5-1 plan	6,333	$63.38	$401k	44%	Form 4
Mar 5	Lee Scott Golden EVP & CHIEF MEDICAL OFFICER	Sold10b5-1 plan	10,000	$63.38	$634k	11%	Form 4
Mar 5	Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER	Sold10b5-1 plan	3,989	$63.38	$253k	3.4%	Form 4
Feb 19	Mark Elliott Boulding EXEC. VP AND CLO	Sold10b5-1 plan 4 parts	3,019	$69.48 average	$210k	2.8%	Form 4
Feb 18	Pierre Gravier CHIEF FINANCIAL OFFICER	Sold10b5-1 plan	2,992	$69.36	$208k	3.3%	Form 4
Feb 18	Matthew B. Klein CHIEF EXECUTIVE OFFICER	Sold10b5-1 plan	7,371	$69.36	$511k	1.9%	Form 4
Feb 18	Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER	Sold10b5-1 plan	2,494	$69.36	$173k	3.4%	Form 4
Feb 18	Lee Scott Golden EVP & CHIEF MEDICAL OFFICER	Sold10b5-1 plan	2,484	$69.36	$172k	2.7%	Form 4
Feb 18	Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER	Sold10b5-1 plan 2 parts	3,121	$69.36 average	$216k	2.6%	Form 4

Oct 1410b5-1 plan
Michael Schmertzler
Director · sold 2,500 at avg $59.61
$149k
0.2% of stake
Oct 910b5-1 plan
Mark Elliott Boulding
EXEC. VP AND CLO · sold 192 at $64.26
$12k
0.2% of stake
Oct 710b5-1 plan
Michael Schmertzler
Director · sold 2,500 at avg $63.39
$158k
0.2% of stake
Oct 5 – 610b5-1 plan
Mark Elliott Boulding
EXEC. VP AND CLO · sold 2,073 at avg $64.06
$133k
1.9% of stake
Sep 3010b5-1 plan
Glenn Jr Md Phd Steele
Director · sold 12,000 at $65.16
$782k
35% of stake
Sep 16 – 1710b5-1 plan
Michael Schmertzler
Director · sold 20,000 at avg $67.49
$1.35M
1.4% of stake
Sep 9 – 1010b5-1 plan
Michael Schmertzler
Director · sold 20,000 at avg $67.59
$1.35M
1.5% of stake
Aug 26 – 2710b5-1 plan
Michael Schmertzler
Director · sold 25,000 at avg $72.26
$1.81M
1.6% of stake
Aug 19 – 2010b5-1 plan
Michael Schmertzler
Director · sold 25,000 at avg $72.22
$1.81M
1.6% of stake
Aug 1710b5-1 plan
Mark Elliott Boulding
EXEC. VP AND CLO · sold 2,813 at avg $72.57
$204k
2.6% of stake
Aug 410b5-1 plan
Matthew B. Klein
CHIEF EXECUTIVE OFFICER · sold 10,292 at $68.57
$706k
2.6% of stake
Jul 1410b5-1 plan
Pierre Gravier
CHIEF FINANCIAL OFFICER · sold 3,494 at $80.35
$281k
4.0% of stake
Jul 910b5-1 plan
Mary L. Smith
Director · sold 15,834 at avg $90.00
$1.43M
42% of stake
Jul 910b5-1 plan
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER · sold 2,464 at $90.25
$222k
3.8% of stake
Jul 6 – 710b5-1 plan
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER · sold 46,774 at avg $87.52
$4.09M
43% of stake
Jul 610b5-1 plan
Mark Elliott Boulding
EXEC. VP AND CLO · sold 5,079 at avg $85.08
$432k
4.6% of stake
Jun 2610b5-1 plan
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER · sold 8,130 at avg $85.26
$693k
11% of stake
Jun 24 – 2510b5-1 plan
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER · sold 26,283 at avg $85.78
$2.25M
30% of stake
Jun 2210b5-1 plan
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER · sold 23,749 at avg $80.90
$1.92M
27% of stake
Jun 1710b5-1 plan
Christine Marie Utter
SVP, CHIEF ACCOUNTING OFFICER · sold 19,686 at $75.56
$1.49M
22% of stake
Jun 1710b5-1 plan
Mark Elliott Boulding
EXEC. VP AND CLO · sold 10,462 at avg $78.65
$823k
9.0% of stake
Jun 1010b5-1 plan
Eric Pauwels
CHIEF BUSINESS OFFICER · sold 21,277 at avg $75.00
$1.6M
22% of stake
May 1510b5-1 plan
Mark Elliott Boulding
EXEC. VP AND CLO · sold 2,812 at avg $72.18
$203k
2.6% of stake
May 1410b5-1 plan
Matthew B. Klein
CHIEF EXECUTIVE OFFICER · sold 12,572 at avg $72.95
$917k
3.1% of stake
May 810b5-1 plan
Mark Elliott Boulding
EXEC. VP AND CLO · sold 3,540 at avg $78.97
$280k
3.3% of stake
Apr 2110b5-1 plan
Matthew B. Klein
CHIEF EXECUTIVE OFFICER · sold 2,850 at $70.91
$202k
0.7% of stake
Apr 610b5-1 plan
Mark Elliott Boulding
EXEC. VP AND CLO · sold 2,265 at avg $69.45
$157k
2.1% of stake
Apr 210b5-1 plan
Lee Scott Golden
EVP & CHIEF MEDICAL OFFICER · sold 829 at $67.99
$56k
1.0% of stake
Apr 110b5-1 plan
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER · sold 52,003 at avg $69.04
$3.59M
45% of stake
Mar 1210b5-1 plan
Matthew B. Klein
CHIEF EXECUTIVE OFFICER · sold 2,662 at $64.08
$171k
0.7% of stake
Mar 1010b5-1 plan
Stephanie Okey
Director · sold 15,167 at avg $70.00
$1.06M
65% of stake
Mar 510b5-1 plan
Stephanie Okey
Director · sold 6,333 at $63.38
$401k
44% of stake
Mar 510b5-1 plan
Lee Scott Golden
EVP & CHIEF MEDICAL OFFICER · sold 10,000 at $63.38
$634k
11% of stake
Mar 510b5-1 plan
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER · sold 3,989 at $63.38
$253k
3.4% of stake
Feb 1910b5-1 plan
Mark Elliott Boulding
EXEC. VP AND CLO · sold 3,019 at avg $69.48
$210k
2.8% of stake
Feb 1810b5-1 plan
Pierre Gravier
CHIEF FINANCIAL OFFICER · sold 2,992 at $69.36
$208k
3.3% of stake
Feb 1810b5-1 plan
Matthew B. Klein
CHIEF EXECUTIVE OFFICER · sold 7,371 at $69.36
$511k
1.9% of stake
Feb 1810b5-1 plan
Christine Marie Utter
SVP, CHIEF ACCOUNTING OFFICER · sold 2,494 at $69.36
$173k
3.4% of stake
Feb 1810b5-1 plan
Lee Scott Golden
EVP & CHIEF MEDICAL OFFICER · sold 2,484 at $69.36
$172k
2.7% of stake
Feb 1810b5-1 plan
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER · sold 3,121 at avg $69.36
$216k
2.6% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PTCT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

PBHPrestige Consumer Healthcare Inc.

ANIPAni Pharmaceuticals Inc.

ACADAcadia Pharmaceuticals Inc.

APLSApellis Pharmaceuticals, Inc.

HRMYHarmony Biosciences Holdings, Inc.

IONSIonis Pharmaceuticals, Inc.

CORTCorcept Therapeutics Incorporated

INSMInsmed Inc.

Spot a number that looks wrong? Check it in PTCT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PTCT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.